-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Pyxis Oncology, Raises Price Target to $7

Benzinga·12/19/2025 12:47:18
Listen to the news
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Pyxis Oncology (NASDAQ:PYXS) with a Buy and raises the price target from $5 to $7.